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ARTICLE IN PRESS

Adult Urology
Perspectives on the Role of Biopsy for
Management of T1 Renal Masses:
Survey Results From Two Regional
Quality Improvement Collaboratives
Zachary J. Prebay, Amit Patel, Anna Johnson, Tae Kim, Claudette Fonshell, Jay D. Raman,
Serge Ginzburg, Robert G. Uzzo, Craig G. Rogers, and Brian R. Lane, for the Pennsylvania
Urologic Regional Collaborative and Michigan Urological Surgery Improvement Collaborative 8,9*
OBJECTIVE

MATERIALS AND
METHODS

RESULTS

CONCLUSION

To understand perspectives on renal mass biopsy, a survey was distributed to urologists in the
Michigan Urological Surgery Improvement Collaborative and Pennsylvania Urologic Regional
Collaborative. Renal mass biopsy (RMB) may reduce treatment of benign renal neoplasms; however, utilization varies widely.
Michigan Urological Surgery Improvement Collaborative and Pennsylvania Urologic Regional
Collaborative are two quality improvement collaboratives that include a “real-world” collection of
urologists from academic- and community-based settings. A 12-item survey assessing current RMB
utilization, patient- and tumor-speciﬁc factors, adverse events, impact on management, and simulated patient scenarios was distributed. Responses are reported using descriptive statistics.
Many responders (n = 54) indicated using RMB in less than 25% of cT1a (59%) and cT1b (85%)
tumors. The most important patient-speciﬁc factors on the decision to recommend RMB were possible metastasis to the kidney (94%), patient comorbidity as a risk factor for active treatment
(89%), and patient age (81%). The most important tumor-speciﬁc factors were the presence of
bilateral tumors (81%), tumor size (70%) and perceived potential of performing nephron-sparing
surgery (67%). Ten responders (19%) noted barriers to RMB in their practice, 23 (43%) recalled
experiences with complications or poor outcomes, and 43 (80%) reported experiences where the
results of RMB altered management. When presented with simulated patients, few urologists (9%20%) recommended RMB in younger patients with any sized mass. Recommendations varied
based on patient age, comorbidity, and tumor size.
Understanding perspectives on RMB usage is essential prior to implementing quality improvement
efforts. Most urologists participating in two statewide collaboratives infrequently recommend
RMB. Optimizing RMB utilization may help reduce unnecessary treatments. UROLOGY 00: 1
−6, 2022. © 2022 Elsevier Inc.
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K

idney cancer contributed >431,000 new cancer
diagnoses worldwide in 2020 with nearly 200,000
deaths.1 Determining the optimal strategy when
counseling patients with a clinical T1 renal mass
(cT1RM) is not straightforward, with many competing
factors to consider.2 Many patients and providers pursue
surgical removal upon discovery of a suspicious cT1RM,3
yet a non-insigniﬁcant number of these tumors are benign
on ﬁnal pathology.4,5 These avoidable surgeries represent
an overall risk to individual patient morbidity and mortality as well as inherent costs to the healthcare system.6
Despite American Urological Association (AUA) guidelines,7 surveillance is uncommonly offered to patients
(6.4%-19.2%) with cT1aRM (≤4 cm) based on reports
from SEER and other national databases,3,8,9 with two
contemporary studies also including patients with
https://doi.org/10.1016/j.urology.2022.01.038
0090-4295
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cT1bRM (>4 to 7 cm) (surveillance rates 6.8%11%).10,11 Rates of partial nephrectomy, instead of radical
nephrectomy, for cT1RM have been increasing in recent
years,3 which limits renal functional loss; but nephrectomy of any kind, instead of surveillance, still carries the
risks of morbidity and mortality from surgery.6 A goal of
quality improvement collaboratives, such as the Michigan
Urologic Surgery Improvement Collaborative (MUSIC)
and the Pennsylvania Urologic Regional Collaborative
(PURC), is to determine how to optimize care for each
individual patient and distribute this learning to the urologic community.
Renal mass biopsy (RMB) has the potential to reduce
unnecessary treatment for benign tumors and better
inform patient selection for surveillance.12,13 It is safe and
can be performed in an ambulatory setting.14,15 Despite
noted beneﬁts and promising safety proﬁle, utilization of
RMB remains limited and highly variable between providers.16 Even the 2017 AUA guidelines give great latitude to the provider regarding which patients to biopsy,
stating that “In the setting of a solid renal mass, RMB is
not required for: (1) young or healthy patients who are
unwilling to accept the uncertainties associated with
RMB; or (2) older or frail patients who will be managed
conservatively independent of RMB ﬁndings.”7 It is
unclear which factors prompt providers to recommend
RMB. Consensus on which patients are most likely to
beneﬁt from RMB is also unclear, as it is likely not necessary in all, or even most, patients.17 Further, although use
of RMB is increasing,18 current U.S. practice patterns
likely underutilize this modality in the diagnostic algorithm.19 Better understanding of perspectives on RMB
could help determine optimal practice.
To address this knowledge gap, a survey was distributed
to urologists at two statewide quality improvement collaboratives. These collaboratives are composed of urologists
from diverse settings, both community- and academicbased, and capture a representative “real-world” sampling
of urologic practice. Herein, we qualitatively describe the
current perspectives on RMB including the patient- and
tumor-speciﬁc factors that may be more likely to prompt
RMB and provider perspectives on simulated patient scenarios.

Survey Design Process
A 12-item survey was designed and distributed electronically
from the MUSIC coordinating center to all active participants
in MUSIC and PURC (see Supplemental Data). Questions were
developed by members of the MUSIC-KIDNEY working group
and the co-directors of MUSIC-KIDNEY gave ﬁnal approval on
survey design. Following approval, the MUSIC coordinating
center distributed the online survey via email. We did not
attempt to pretest the survey outside of the KIDNEY working
group or attempt to account for non-response bias.
Survey Content
The ﬁrst two questions assessed urologist’s RMB utilization patterns for patients with cT1a and cT1b tumors. Respondents
then reviewed four patient scenarios assuming all masses were
solid, enhancing, and in an RMB amenable location. Simulated
patients included a 45-year-old healthy patient, a 60-year-old at
risk for CKD, a 60-year-old with CKD, and an 80-year-old sickly
patient. Scenarios asked whether RMB would be recommended
for tumors 1-, 2-, 4- and 6-cm for each simulation.
Urologists next identiﬁed levels of importance for six patientspeciﬁc factors and six tumor-speciﬁc factors in deciding to recommend RMB. Patient factors included: age, comorbidity,
patient preference, anticoagulation use, previous treatments,
and possible metastasis to kidney. Tumor factors included: size,
location, complexity, cystic features, bilaterality, and nephronsparing-surgery potential. Relative importance was gauged for
each factor using 5-point Likert-styled questions, ranging from
“not important” to “very important” and included the option to
respond with “no opinion”. Responses of “important” and “very
important” were combined when reporting results.
Next, the survey assessed potential barriers to RMB. Providers
were asked what the likelihood of them performing RMB in
clinic would be on a 5-point Likert scale ranging from “none” to
“very likely”. Finally, providers were asked about their experience with adverse outcomes or altered management following
RMB and to provide examples.
The aim of this study was to use descriptive statistics to qualitatively describe the responses to each survey question and thus
capture a representative picture of provider beliefs across the two
collaboratives. We collected the number and percentage of survey participants who responded to each question and report the
results accordingly. We present this study in alignment with
STROBE guidelines, as applicable, adapted for cross-sectional
surveys.22

RESULTS
MATERIALS AND METHODS
Survey Population - Quality Improvement Collaboratives
MUSIC was created with support by Blue Cross Blue Shield of
Michigan to design quality improvement efforts aimed at
improving urologic care in the state of Michigan. MUSIC
includes over 200 Urologists from 50 practices.20 In 2016,
MUSIC established Kidney mass: (Identifying and Deﬁning
Necessary Evaluation and therapY (MUSIC-KIDNEY) as a quality improvement initiative for patients with renal masses ≤7 cm
(cT1RM).21 PURC was established in 2015 with funding in part
from the Partnership for Patient Care/Health Care Improvement
Foundation. PURC includes 140 Urologists from 11 practices in
Pennsylvania and 2 practices in New Jersey.
2

In total, 54 urologists responded, representing a 15.9% response
rate. For cT1a and cT1b tumors, respectively, 0% and 19% indicated they would never pursue RMB, 59% and 67% pursue
RMB less than 25% of the time, 28% and 11% pursue RMB
25%-50% of the time, 7% and 0% pursue RMB 51%-75% of the
time, and 6% and 4% pursue RMB >75% of the time (Fig. 1).
Recommendations for the simulated patient scenarios varied
based on the select combination of tumor size and patient health
(Fig. 2). Few recommended RMB for the 45-year-old patient
(9%-20%). The only scenario with over 50% of urologists recommending RMB was the 60-year-old patient with CKD and a
4-cm tumor (61%). Recommendations for RMB for this hypothetical patient ranged from 15% for the 1-cm mass to 61%. For
the 60-year-old at risk for CKD, recommendations ranged from
UROLOGY 00 (00), 2022
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Figure 1. Frequency of recommendations for renal mass
biopsy (RMB) for T1a and T1b masses. (Color version available online.)

Figure 2. Recommendations for renal mass biopsy (RMB)
based on simulated patient scenarios. (Color version available online.)
17% for a 1-cm mass to 39% for a 2-cm mass. Finally, recommendations for the 80-year-old sick patient ranged from 13% for
the 1-cm mass to 43% for both the 4- and 6-cm masses.
The most reported patient factor was the mass representing
possible metastasis, which 94% of urologists described as “important” or “very important” in their decision to recommend RMB
(Fig. 3). Patient comorbidity (89%), age (81%), and patient

preference (80%) were also commonly reported. Previous treatment history (54%) and anticoagulant use (44%) were less commonly reported.
The most common tumor factor reported to impact the decision to perform RMB was the presence of bilateral masses
(81%). This was followed by tumor size (81%), difﬁculty to perform nephron sparing surgery (67%), cystic features (57%),
tumor location (54%), and tumor complexity (39%).
Ten (19%) urologists reported a perceived barrier to RMB: 8
reported concerns with collecting or interpreting the biopsy, 1
suggested the potential of deﬁnitive treatment being delayed,
and 1 responded “Other” but did not expand further. Most (41,
75.9%) responded they were unlikely to consider performing
RMB in clinic (“none” or “not likely”).
Regarding experience with post-RMB adverse effects and circumstances in which RMB impacted management; 23 (43%)
reported experiencing an adverse outcome after RMB, most
commonly excessive bleeding (n = 18). Also reported was pseudoaneurysm (n = 2), pneumothorax (n = 1), ﬁstula (n = 1), and
local recurrence (n = 1) after RMB. Most (n = 45, 83%) recalled
an experience when RMB altered management, 32 recalled
RMB leading them to avoid surgery altogether, including 17
who speciﬁcally mentioned RMB diagnosing oncocytoma. Other
examples include 8 mentioned diagnosing metastasis from
another primary cancer and 1 found an aggressive tumor in an
elderly patient prompting radical nephrectomy.

DISCUSSION
The AUA guidelines avoid prescriptive statements regarding RMB for solid renal masses. The 2017 guidelines state
that “RMB is not required for (1) young or healthy
patients who are unwilling to accept the uncertainties
associated with RMB; or (2) older or frail patients who
will be managed conservatively independent of RMB ﬁndings.” The 2021 update adds the statement that, “In the
setting of a solid renal mass, RMB should be obtained on
a utility-based approach whenever it may inﬂuence management,” continuing to give great latitude to physicians

Figure 3. Importance of individual patient (Red) and tumor factors (Blue) on provider decision to recommend biopsy. (Color
version available online.)
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managing such patients.7 By leveraging membership in
two active U.S. urology collaboratives, this survey is
uniquely able to capture a “real-world” sampling of perspectives on RMB, which should allow for the results to
be generalizable to many practicing urologists (at least in
the United States). In addition, subsequent analyses of
actual use of RMB and QI activities within these collaboratives are ways to further engage these same practitioners.
We established current practice patterns of RMB for
cT1RM, captured how recommendations change based
on patient and tumor status via simulated patient scenarios, and assessed factors that may prompt urologists to recommend RMB.
Most urologists in this survey study reported using RMB
infrequently. For cT1aRM, 13% stated they use RMB
over 50% of the time and only 4% answered the same for
cT1bRM. MUSIC-KIDNEY collects data on RMB utilization, with 167 RMB in 965 patients (17.3%) recorded in
our most recent analysis of registry data.23 As the completed surveys were anonymous, we cannot compare survey responses to individual provider practice. Further
work could be taken to analyze whether actual biopsy utilization reﬂects the factors suggested to be important in
this study. Urologists in these two collaboratives may be
more favorable toward RMB when compared to members
of the AUA at large.24 Patel et al reported that 31.8% of
urologists would never consider RMB for cT1a tumors,
while in our collaboratives no respondent indicated they
would never consider RMB for tumors of that size. However, 59% would rarely (<25%) use RMB for cT1a masses
which may reﬂect differences in survey design rather than
practice.
Identifying factors that inﬂuence providers’ decisions to
recommend RMB is necessary to examine possible selection biases in current datasets evaluating RMB and surgery
for cT1RM. Important factors for considering RMB share
considerable overlap with those that impact treatment
decisions.3 Perhaps unsurprisingly, patient age (81%) and
comorbidities (89%) were important, along with the possibility of the tumor being a metastasis (94%). Importantly, our simulated patient exercises demonstrate that
these are not linear relationships (increasing age 6¼ higher
likelihood to biopsy, more comorbidity 6¼ more likely to
biopsy), and instead emphasizes the multifactorial decision-making as opposed to directionally directed by any
individual factor. Younger patients were uncommonly recommended to undergo RMB (9%-20%). Presumably,
these patients were felt to beneﬁt from treatment regardless of biopsy results. Sicker, elderly patients with smaller
masses were also unlikely to be recommended RMB
(13%-22%), as they may be more suitable for imagingbased surveillance or watchful waiting independent of the
results of RMB. These clinical practice patterns have been
surmised in AUA guidelines,7 but our survey captures this
information directly using speciﬁc benchmark patient scenarios. Along with age and comorbidities, sex and race
have been described as factors that impact RMB utilization,25 which may reﬂect perceived differences in tumor
4

incidence and biology. Tumor size and complexity, as well
as the potential for nephron sparing surgery, also inﬂuence
RMB decisions. RMB utilization in the Clinical Research
Ofﬁce of the Endourological Society Small Renal Mass
registry was 11.6% prior to extirpative surgery.26 Biopsy
was more commonly performed in patients with higher
co-morbidities, multiple/bilateral tumors, or other malignancies. Shahait and colleagues found higher rates of
pathological upstaging to pT3a in the RMB cohort and
use of radical nephrectomy was higher than in patients
undergoing surgery without prior RMB, as has been
reported. Previously, in each of the prior studies, it is the
minority of patients that are undergoing RMB,12,13,15,16,26
consistent with the ﬁndings in this study.
Despite the results presented within, it remains unclear
what potential combinations or cut-offs of these factors
providers should use. For example, many providers view
cystic masses as a contra-indication for RMB, while others
offer it. Cystic features have been noted to be independent predictors of non-diagnostic RMB27 and recommendations could more speciﬁcally state how to incorporate
cystic ﬁndings into decision-making. Working groups for
the European Association of Urology developed a model
to help determine optimal candidates for RMB28 but
noted that it is incomplete regarding patient factors that
may inﬂuence RMB recommendations. Efforts are underway within MUSIC to deﬁne patients that are likely to
beneﬁt from surveillance; a similar methodology could be
applied to determine which patients may beneﬁt from
RMB. Together, these decision support tools can help
determine how to incorporate RMB and subsequent
results into a decision to pursue surveillance.
For seven of the twelve scenarios presented, between
37% and 61% of providers recommended RMB, suggesting differences of opinion that may be better elucidated by
dialogue. Within our collaboratives, we have opportunities to do this at collaborative meetings, virtual meetings,
and panel discussions. Following discussion, providers
would likely beneﬁt from updated, evidence-driven guidance on which groups of patients should undergo RMB.
Utilizing the power of the collaborative to gather this evidence and generate consensus are future directions that
the MUSIC-KIDNEY group has interest in studying.
Around one-ﬁfth of respondents noted barriers to RMB
and almost half recalled adverse outcomes following
RMB. The largest barrier was concern with collecting and
interpreting RMB. This may reﬂect the dual concerns of
the noted rate of non-diagnostic procedures and the
potential for procedural complications.29 This represents
an opportunity for multidisciplinary collaboration; multiple viable outcomes exist, including innovative machine
learning technologies that could help pathologists interpret samples in the future. RMB workshops could be facilitated by the collaboratives to improve proﬁciency with
the procedure. Alternatively, urologists could learn a technique for in-ofﬁce biopsy that is gaining in popularity
across the country.14 Regarding potential adverse events,
the data shows that RMB is safe, with serious
UROLOGY 00 (00), 2022
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complications being rare,15,29 although the recorded anecdotes indicate that adverse outcomes have the potential to
delay or escalate care. Notably, many urologists reported
an instance in which RMB inﬂuenced management,
including 32 (59% of respondents) who recalled circumstances in which RMB led patients to avoid surgery. This
supports the overarching goal to optimize care for each
individual patient and reduce unnecessary treatments.
Additionally, the use of initial observation (at least 120
days) within MUSIC is higher than observed in most
other reports (53.5% for cT1a and 29.9% for cT1b),23
which perhaps suggests our collaboratives’ focus on decision-making for cT1RM may be impacting treatment
selection for contemporary patients.
It is worth discussing this study’s limitations, including
the inherent limitations of surveys. Although we leveraged two large quality improvement collaboratives to capture “real-world” perspectives on RMB, not every
provider completed the survey, and these results are subject to bias from response rate. The results are also subject
to recall bias; providers’ memory of their current RMB
practice patterns may differ from their actual practice. We
did not attempt to analyze provider demographics that
may be associated with utilization of RMB (such as academic vs private practice), as this was an anonymous survey, but this is a concurrent area of study. The
generalizability of the study may be limited by its inclusion
of only U.S. urologists. It must also be mentioned that this
survey was not designed to capture how often a RMB
inﬂuences management. Instead, we note that RMB can
inﬂuence management, but how often this occurs is a fair
question to ask.
This study has important implications for future quality
improvement efforts. Ultimately, within our collaboratives, the goal is to provide the optimal treatment for each
individual patient. We were able to gain better understanding of current provider perspectives regarding RMB
and identify areas for future study and intervention. The
results were a focus of discussion at a MUSIC collaborative-wide meeting, and we have planned a consensus
panel based on the Rand methodology30 in follow-up to
propose
criteria
in
who
to
recommend
biopsy. Additionally, identifying how providers would
respond to a negative or inconclusive biopsy considering
the known, limited negative predictive value could help
guide preoperative planning. These steps to identify
which patients are most likely to beneﬁt from RMB and
how to best incorporate RMB into clinical care pathways
will likely shift the balance to maximize patient beneﬁt
while minimizing non-diagnostic examinations and
adverse outcomes.

CONCLUSION
We describe the results of a survey distributed to urologists
participating in one of two large Quality Improvement
Collaboratives designed to capture perspectives on RMB.
Urologists currently practice limited use of RMB and

identiﬁed that age, comorbidity, and tumor size, among
other factors, impact utilization. Efforts to better understand the optimal use of RMB and the barriers to greater
implementation of RMB are future quality improvement
initiatives.
Acknowledgment. The corresponding author thank Betz Family Endowment for Cancer Research for their continued support.
Funding was provided in part by the Spectrum Health Foundation and from Blue Cross Blue Shield of Michigan. The authors
also thank Sabrina Noyes for administrative support.

SUPPLEMENTARY MATERIALS
Supplementary material associated with this article can
be found in the online version at https://doi.org/10.1016/
j.urology.2022.01.038.
References
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
2. Chandrasekar T, Boorjian SA, Capitanio U, et al. Collaborative
review: factors inﬂuencing treatment decisions for patients with a
localized solid renal mass. Eur Urol. 2021;80:575–588.
3. Doolittle J, Piotrowski J, Zuk K, et al. Evolving trends for selected
treatments of T1a renal cell carcinoma. Urology. 2019;132:136–142.
4. Bauman TM, Potretzke AM, Wright AJ, et al. Partial nephrectomy
for presumed renal-cell carcinoma: incidence, predictors, and perioperative outcomes of benign lesions. J Endourol. 2017;31:412–417.
5. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis
of pathological features related to tumor size. J Urol.
2003;170:2217–2220.
6. Moskowitz D, Chang J, Ziogas A, et al. Treatment for T1a renal cancer substratiﬁed by size: "Less is More". J Urol. 2016;196:1000–1007.
7. Campbell SC, Uzzo RG, Karam JA, et al. Renal mass and localized
renal cancer: evaluation, management, and follow-up: AUA Guideline: Part II. J Urol. 2021;206:209–218.
8. Palumbo C, Mistretta FA, Knipper S, et al. Assessment of local
tumor ablation and non-interventional management versus partial
nephrectomy in T1a renal cell carcinoma. Minerva Urol Nefrol.
2020;72:350–359.
9. Xing M, Kokabi N, Zhang D, et al. Comparative effectiveness of
thermal ablation, surgical resection, and active surveillance for T1a
renal cell carcinoma: a Surveillance, Epidemiology, and End Results
(SEER)-Medicare-linked
Population
Study.
Radiology.
2018;288:81–90.
10. Maurice MJ, Zhu H, Kiechle JE, et al. Nonclinical factors predict
selection of initial observation for renal cell carcinoma. Urology.
2015;86:892–899.
11. Yang G, Villalta JD, Meng MV, et al. Evolving practice patterns for
the management of small renal masses in the USA. BJU Int.
2012;110:1156–1161.
12. Patel HD, Nichols PE, Su ZT, et al. Renal mass biopsy is associated
with reduction in surgery for early-stage kidney cancer. Urology.
2020;135:76–81.
13. Rahbar H, Bhayani S, Stifelman M, et al. Evaluation of renal mass
biopsy risk stratiﬁcation algorithm for robotic partial nephrectomy
−could a biopsy have guided management? J Urol. 2014;192:1337–
1342.
14. Dave CN, Seifman B, Chennamsetty A, et al. Ofﬁce-based ultrasound-guided renal core biopsy is safe and efﬁcacious in the management of small renal masses. Urology. 2017;102:26–30.
15. Marconi L, Dabestani S, Lam TB, et al. Systematic review and metaanalysis of diagnostic accuracy of percutaneous renal tumour biopsy.
Eur Urol. 2016;69:660–673.

UROLOGY 00 (00), 2022
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 10, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

5

ARTICLE IN PRESS
16. Ozambela Jr. M, Wang Y, Leow JJ, et al. Contemporary trends in
percutaneous renal mass biopsy utilization in the United States. Urol
Oncol. 2020;38:835–843.
17. Kutikov A, Smaldone MC, Uzzo RG, et al. Renal mass biopsy:
always, sometimes, or never? Eur Urol. 2016;70:403–406.
18. Patel DN, Ghali F, Meagher MF, et al. Utilization of renal mass
biopsy in patients with localized renal cell carcinoma: a populationbased study utilizing the National Cancer Database. Urol Oncol.
2021;39. 79 e71-79 e78.
19. McClure T, Sedrakyan A, LaRussa S, et al. Underutilization of renal
mass biopsy: surveillance using the medicare database between 2004
and 2016. J Vasc Interv Radiol. 2020;31:854–857.
20. Montie JE, Linsell SM, Miller DC. Quality of care in urology and
the Michigan urological surgery improvement collaborative. Urol
Pract. 2014;1:74–78.
21. Noyes SL, Kim T, Johnson A, et al. Quality of care for renal masses:
the Michigan Urological Surgery Improvement Collaborative - kidney mass: identifying & deﬁning necessary evaluation & therapy
(MUSIC-KIDNEY). Urol Pract. 2020;7:507–514.
22. von Elm E, Altman DG, Egger M, et al. The strengthening the
reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med.
2007;4:e296.
23. Patel AK, Rogers CG, Johnson A, et al. Initial observation of a large
proportion of patients presenting with clinical stage T1 renal masses:

6

24.

25.

26.

27.

28.

29.

30.

results from the MUSIC-KIDNEY Statewide Collaborative. Eur
Urol Open Sci. 2021;23:13–19.
Patel RM, Saﬁullah S, Okhunov Z, et al. Pretreatment diagnosis of
the small renal mass: status of renal biopsy in the United States of
America. J Endourol. 2018;32:884–890.
Leppert JT, Hanley J, Wagner TH, et al. Utilization of renal mass
biopsy in patients with renal cell carcinoma. Urology. 2014;83:774–
779.
Shahait M, Jackman S, Landman J, et al. Utilization and operative inﬂuence of renal mass biopsy in the small renal mass:
analysis from the Clinical Research Ofﬁce of the Endourological Society Small Renal Mass registry. J Endourol. 2020;34:99–
106.
Prince J, Bultman E, Hinshaw L, et al. Patient and tumor characteristics can predict nondiagnostic renal mass biopsy ﬁndings. J Urol.
2015;193:1899–1904.
Martini A, Larcher A, Bravi CA, et al. How to select the optimal candidates for renal mass biopsy. Eur Urol Oncol. 2021;4:
506–509.
Posielski NM, Bui A, Wells SA, et al. Risk factors for complications
and nondiagnostic results following 1,155 consecutive percutaneous
core renal mass biopsies. J Urol. 2019;201:1080–1087.
Cher ML, Dhir A, Auffenberg GB, et al. Appropriateness criteria for active surveillance of prostate cancer. J Urol. 2017;197:
67–74.

UROLOGY 00 (00), 2022
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 10, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

